Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 6/20 | 0.77 |
| ▸ | HTR2C | P28335 | 2/20 | 0.63 |
| ▸ | MAPT | P10636 | 5/20 | 0.57 |
| ▸ | TP53 | P04637 | 3/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | FAAH | O00519 | 6/20 | 0.53 |
| ▸ | NPC1 | O15118 | 4/20 | 0.53 |
| ▸ | RAB9A | P51151 | 3/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2927911 | 0.99 | MCHR1 (0.75) | MCHR1HTR2CMAPTTP53LMNA | |
| SCHEMBL6304593 | 0.96 | MCHR1 (0.70) | MCHR1HTR2CMAPTTP53LMNA | |
| SCHEMBL6314183 | 0.91 | MCHR1 (0.65) | MCHR1HTR2CMAPTTP53LMNA | |
| SCHEMBL6304597 | 0.91 | MCHR1 (0.65) | MCHR1HTR2CMAPTTP53LMNA | |
| SCHEMBL6314243 | 0.91 | MCHR1 (0.65) | MCHR1HTR2CMAPTTP53LMNA | |
| SCHEMBL6307407 | 0.91 | MCHR1 (0.65) | MCHR1HTR2CMAPTTP53LMNA | |
| SCHEMBL6313616 | 0.91 | MCHR1 (0.69) | MCHR1HTR2CMAPTTP53LMNA | |
| SCHEMBL6306508 | 0.91 | MCHR1 (0.69) | MCHR1HTR2CMAPTTP53LMNA | |
| SCHEMBL2920670 | 0.90 | MCHR1 (0.79) | MCHR1HTR2CFAAHSMN1; SMN2 | |
| SCHEMBL2925998 | 0.90 | MCHR1 (0.77) | MCHR1HTR2CMAPTTP53LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1285651-B1 | MELANIN CONCENTRATING HORMONE ANTAGONISTS | TAKEDA PHARMACEUTICAL (JP) | 2010-09-01 | — | — | EP | disclosed |
| US-6930185-B2 | Melanin-concentrating hormone antagonist | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2005-08-16 | — | — | US | disclosed |
| US-20040077628-A1 | Melanin-concentrating hormone antagonist | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-04-22 | — | — | US | disclosed |
| EP-1285651-A1 | MELANIN CONCENTRATING HORMONE ANTAGONISTS | Takeda Chemical Industries, Ltd. (JP) | 2003-02-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077628-A1 | Melanin-concentrating hormone antagonist | MCHR1, MC1R, MCHR2 | MCHR1 1/4885HTR2C 107/4885MAPT 3638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.